Melinta Therapeutics, Inc.
http://www.melinta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Melinta Therapeutics, Inc.
Tech Transfer Roundup: Sanofi Gets IP For Multiple Myeloma From Memorial Sloan Kettering
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Public/Private Partnerships Keep Gonorrhea Drug Development Alive
Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Rib-X Pharmaceuticals, Inc.
- Cempra, Inc. (Cempra Pharmaceuticals, Inc.)